PRISYM 360 SaaS clinical trials solution will help RxSource streamline its operations

PRISYM ID has announced that Global Clinical Trial Supplies Specialist RxSource has invested in the PRISYM 360 clinical labelling platform. The software will enable RxSource to optimize its demand-led secondary packaging and labelling services, and supply medicines faster.

RxSource specializes in the ethical sourcing, packaging and delivery of medicines for Clinical Trials, Research and Development and Expanded Access Programs. They will now be able to design and create labels in-house using the cloud-based PRISYM 360 clinical trials labelling solution from PRISYM ID. 

This is a critical advantage for RxSource, which has offices in the US, Canada and Ireland. They have seen a rise in demand for its services during the pandemic as drug shortages and patient recruitment have proved problematic for many companies in the clinical trials sector. 

The PRISYM 360 platform optimizes label management processes, allowing users to build up a library of approved language translations and automatically apply regulatory rules and intelligence to label content. This reduces the complexity and time traditionally involved in clinical labelling. 

By offering a cloud-based version of its clinical trials labelling platform, PRISYM ID supports the life sciences sector’s need for ever more agility.   

Rhys Evans, Senior Director, CTS & Global Supply at RxSource, said: “The PRISYM 360 platform is a valuable service offering for our business because it will enable us to package and supply medicines in as little as 48 hours. With shorter lead times and our own automated in-house labelling and printing system, we can ensure regulatory compliance.”

Warren Stacey, SVP of Global Sales at PRISYM ID, added: “We are very pleased that RxSource has invested in our cloud-based clinical trials labelling solution, PRISYM 360, which provides a straightforward and cost-effective solution for companies that want to streamline this critical aspect of their business. It mitigates the complexity and risk involved in clinical labelling, giving customers reassurance that their labels and booklets are fully compliant, and enabling them to take control of the design and printing process in-house.”